TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22971742

Group type: EXPERIMENTAL
Intervention: midazolam + tramadol (1 mg/kg)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: midazolam + saline
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control (no additional medication)
Number of subjects: 87
Study: 21514637

Group type: EXPERIMENTAL
Intervention: Methotrexate (10-22.5 mg/wk)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Azathioprine (1.5-2.5 mg/kg/d)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Methotrexate and Azathioprine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 42
Study: 18030515

Group type: EXPERIMENTAL
Intervention: NSAID therapy followed by methotrexate (MTX) for 3 months after 3 months of NSAID therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Combination of NSAID and MTX for the entire 6-month period
Number of subjects: 35
Study: 17205826

Group type: EXPERIMENTAL
Intervention: Compound decoctum of Tripterygium wilfordii (TW) and liquorice
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tripterygium wilfordii ployglycosidium tablets
Number of subjects: 120
Study: 14638353

Group type: EXPERIMENTAL
Intervention: Vitamins E and C (1000 IU and 1000 mg, respectively) daily for 6 months
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 11125871

Group type: EXPERIMENTAL
Intervention: Midazolam 12 mg + Caffeine 250 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Midazolam 12 mg + Caffeine 125 mg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Midazolam 12 mg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Caffeine 250 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 108
Study: 8797215

Group type: EXPERIMENTAL
Intervention: Continuous-Interleaved-Sampling (CIS) strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spectral-Peak (SPEAK) strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multipeak (MPEAK) strategy
Number of subjects: 0
Study: 1624973

Group type: EXPERIMENTAL
Intervention: Refraining from consuming soft drinks
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Refraining from consuming soft drinks (for those consuming phosphoric acid drinks)
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Refraining from consuming soft drinks (for those consuming citric acid drinks)
Number of subjects: 1009
Study: 6439836

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) and methyl‐CCNU
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 5‐FU, Adriamycin, and methyl‐CCNU
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 5‐FU, Adriamycin, and mitomycin C
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Adriamycin and mitomycin C alone
Number of subjects: 222

Group type: COMPARATOR
Intervention: Adriamycin and mitomycin C
Number of subjects: 222
Study: 31092895

Group type: EXPERIMENTAL
Intervention: Once-weekly carfilzomib 70 mg/m2 (Kd70 mg/m2)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Twice-weekly carfilzomib 27 mg/m2 (Kd27 mg/m2)
Number of subjects: 469
Study: 28259322

Group type: EXPERIMENTAL
Intervention: Combination analgesics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27185684

Group type: EXPERIMENTAL
Intervention: Reinforced tracheal tubes
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard polyvinyl chloride tracheal tubes
Number of subjects: 76
Study: 25150183

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 33 °C
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 36 °C
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (not specified, but implied as TTM not applied)
Number of subjects: 169
Study: 22097972

Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) 10 mg daily
Number of subjects: 480
Study: 19638620

Group type: EXPERIMENTAL
Intervention: Prediagnostic serum concentration of soluble CD30 (sCD30)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (first quartile of sCD30)
Number of subjects: 234
Study: 17941284

Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride, 30 mg, twice daily for 2 weeks
Number of subjects: 453

Group type: COMPARATOR
Intervention: Placebo, twice daily for 2 weeks
Number of subjects: 453
Study: 16360521

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency dissection tonsillectomy (BRDT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy (CDT)
Number of subjects: 200
Study: 11562661

Group type: EXPERIMENTAL
Intervention: Gelatin-coated Dacron (GEL-D) grafts (n = 109)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Collagen-coated Dacron (COL-D) grafts (n = 100)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Stretch polytetrafluoroethylene (PTFE) grafts (n = 106)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Gelatin-coated Dacron (GEL-D) grafts
Number of subjects: 315

Group type: COMPARATOR
Intervention: Collagen-coated Dacron (COL-D) grafts
Number of subjects: 315

Group type: COMPARATOR
Intervention: Stretch polytetrafluoroethylene (PTFE) grafts
Number of subjects: 315

Group type: COMPARATOR
Intervention: Dacron grafts (GEL-D and COL-D combined)
Number of subjects: 315
Study: 9622279

Group type: EXPERIMENTAL
Intervention: 0.5, 1 or 2 mg/day of oral micronized 17beta‐estradiol
Number of subjects: 18
Study: 7841755

Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhiza (SM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (22 healthy subjects)
Number of subjects: 30
Study: 3216364

Group type: EXPERIMENTAL
Intervention: Cefamandole (1-g intravenous dose)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Cefotaxime (1-g intravenous dose)
Number of subjects: 223
Study: 30479292

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard of care plus increased educational information regarding bowel preparation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard of care plus increased educational information regarding bowel preparation plus an anti-flatulent medication
Number of subjects: 30
Study: 27641791

Group type: EXPERIMENTAL
Intervention: 4h sleep with 0.28Hz horizontal linear oscillation
Number of subjects: 4

Group type: COMPARATOR
Intervention: 8h sleep with stationary conditions
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 4h sleep with stationary conditions
Number of subjects: 4

Group type: COMPARATOR
Intervention: 8h sleep with 0.28Hz horizontal linear oscillation
Number of subjects: 4
Study: 25012163

Group type: EXPERIMENTAL
Intervention: ApoA2 (fourth quartile)
Number of subjects: 1255

Group type: COMPARATOR
Intervention: HDL cholesterol and apoA1 and apoC3 quartiles
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: ApoA2
Number of subjects: 1255
Study: 24125675

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance plus nerve stimulation (group US-NS)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Ultrasound guidance alone (group US)
Number of subjects: 166
Study: 21914207

Group type: EXPERIMENTAL
Intervention: Written invitation letter to spouses of new antenatal attendees
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Information letter and leaflet concerning antenatal care (Control)
Number of subjects: 1060
Study: 19028275

Group type: EXPERIMENTAL
Intervention: Radiotherapy for early-stage Hodgkin's lymphoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contemporary therapeutic approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study: 17163273

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day + Amoxicillin 1500 mg/day + Clarithromycin 400 mg/day
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day + Amoxicillin 1500 mg/day + Clarithromycin 800 mg/day
Number of subjects: 288
Study: 14586049

Group type: EXPERIMENTAL
Intervention: RDS group (neutrophil apoptosis on day 7 BAL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: BAL fluid from RDS patients (day 1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: BAL fluid from RDS patients (day 2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ECMO survivors (day 1)
Number of subjects: 32
Study: 10760376

Group type: EXPERIMENTAL
Intervention: Amino acid mixture without tryptophan (depletion group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 24
Study: 9032182

Group type: EXPERIMENTAL
Intervention: Plasma hypoxanthine levels in ARDS nonsurvivors (37.48 +/- 3.1 microM)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Plasma hypoxanthine levels in ARDS survivors (15.24 +/- 2.09 microM)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Plasma hypoxanthine levels in patients undergoing pulmonary resection (9.22 +/- 1.89 microM)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Plasma hypoxanthine levels in patients with sepsis (1.12 +/- 0.69 microM)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Plasma hypoxanthine levels in normal healthy controls (1.43 +/- 0.38 microM)
Number of subjects: 4
Study: 8314475

Group type: EXPERIMENTAL
Intervention: High dose interferon (10 million units (MU) given six times a week for two weeks followed by 12 weeks of thrice weekly dosing
Number of subjects: 126

Group type: COMPARATOR
Intervention: Eight weeks of 10 MU interferon six times a week
Number of subjects: 126

Group type: COMPARATOR
Intervention: Four weeks of 10 MU six times a week followed by eight weeks of thrice weekly dosing
Number of subjects: 126
Study: 2963306

Group type: EXPERIMENTAL
Intervention: Combination of a third generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacin)
Number of subjects: 33
Study: 31420665

Group type: EXPERIMENTAL
Intervention: PS-LED (cool poultry specific LED)
Number of subjects: 20

Group type: COMPARATOR
Intervention: ICD (incandescent)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Short/non-intermittent photoperiod (8L:16D)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular/intermittent photoperiod (2L:2D)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Strain A and B
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Feed conversion, fat, tender, and yield
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Photoperiod, light sources, or their interactions
Number of subjects: 20
Study: 28675520

Group type: EXPERIMENTAL
Intervention: SB5
Number of subjects: 189

Group type: COMPARATOR
Intervention: EU‐ADL
Number of subjects: 189

Group type: COMPARATOR
Intervention: US‐ADL
Number of subjects: 189
Study: 26371168

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24148712

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (no Tranexamic acid)
Number of subjects: 53
Study: 21340523

Group type: EXPERIMENTAL
Intervention: MISPTT (minimally invasive stereotactic puncture and thrombolysis therapy)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional craniotomy (CC)
Number of subjects: 122
Study: 19794171

Group type: EXPERIMENTAL
Intervention: Translaminar screws
Number of subjects: 120

Group type: COMPARATOR
Intervention: Transforaminal lumbar interbody fusion
Number of subjects: 120
Study: 17448764

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 42

Group type: COMPARATOR
Intervention: Myectomy of the internal anal sphincter (IAS)
Number of subjects: 42
Study: 15337974

Group type: EXPERIMENTAL
Intervention: Short 30‐G x 0.40 x 6 mm gauge needle
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional 25‐G x 0.50 x 13 mm gauge needle
Number of subjects: 37
Study: 12023755

Group type: EXPERIMENTAL
Intervention: Lumbar nerve root decompression surgery in elderly patients
Number of subjects: 44

Group type: COMPARATOR
Intervention: Lumbar nerve root decompression surgery in younger patients (30-50 years)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Lumbar nerve root decompression surgery in both groups
Number of subjects: 44
Study: 11907928

Group type: EXPERIMENTAL
Intervention: Continuous conjugated estrogens (Premarin) and cyclic medroxyprogesterone acetate (Provera)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 7905086

Group type: EXPERIMENTAL
Intervention: Björk-Shiley convexo-concave valves
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 70 degrees valves
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 60 degrees valves
Number of subjects: 22
Study: 2689427

Group type: EXPERIMENTAL
Intervention: 4-h preexercise carbohydrate feeding (M-4)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 8-h preexercise carbohydrate feeding (M-8)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 4-h preexercise with carbohydrate feedings during exercise (M-4CHO)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 8-h preexercise with carbohydrate feedings during exercise (M-8CHO)
Number of subjects: 7
Study: 141644

Group type: EXPERIMENTAL
Intervention: Brief, intense transcutaneous electrical stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study: 42410

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31162183

Group type: EXPERIMENTAL
Intervention: S2 alar iliac (S2AI) screws
Number of subjects: 64
Study: 28385290

Group type: EXPERIMENTAL
Intervention: High-fat meal (HFM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Moderate-fat meal (MFM)
Number of subjects: 8
Study: 25495720

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100mg
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300mg
Number of subjects: 714

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 714
Study: 23657457

Group type: EXPERIMENTAL
Intervention: Breakfasts prepared with virgin olive oil (400 μg mL(‐1) of phenolic compounds)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breakfasts prepared with sunflower oils (pure, enriched with dimethylsiloxane, and enriched with phenolic compounds)
Number of subjects: 0
Study: 20735877

Group type: EXPERIMENTAL
Intervention: Tomato purée (70 g)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (buttered roll without tomato purée)
Number of subjects: 19
Study: 19465371

Group type: EXPERIMENTAL
Intervention: Manual therapy, exercise, and intermittent cervical traction (MTEXTraction group)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Manual therapy, exercise, and sham intermittent cervical traction (MTEX group)
Number of subjects: 81
Study: 17555561

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 34

Group type: COMPARATOR
Intervention: Comparison of Anastrozole and Letrozole
Number of subjects: 34
Study: 15223728

Group type: EXPERIMENTAL
Intervention: Losartan 50-100 mg o.d.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5-25 mg o.d.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study: 11966693

Group type: EXPERIMENTAL
Intervention: Short-contact dithranol cream followed by clobetasol-17-propionate ointment 5 days per week
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Short-contact dithranol cream followed by vehicle of clobetasol-17-propionate ointment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clobetasol-17-propionate ointment 5 days per week
Number of subjects: 12
Study: 9809891

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 741

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 741
Study: 7714225

Group type: EXPERIMENTAL
Intervention: Oral progesterone 300 mg plus intravenous triazolam
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous triazolam plus oral placebo
Number of subjects: 16
Study: 2760949

Group type: EXPERIMENTAL
Intervention: MAST
Number of subjects: 911

Group type: COMPARATOR
Intervention: No‐MAST
Number of subjects: 911
Study: 180197

Group type: EXPERIMENTAL
Intervention: Local applications of human leukocyte interferon (3-4 X 10(4) units per day)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Thermocautery plus human leukocyte interferon
Number of subjects: 73

Group type: COMPARATOR
Intervention: Thermocautery plus mock human leukocyte interferon
Number of subjects: 73
Study: 31352597

Group type: EXPERIMENTAL
Intervention: Canned food
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fresh food
Number of subjects: 20
Study: 25056368

Group type: EXPERIMENTAL
Intervention: Cariprazine 3-12 mg/day
Number of subjects: 236
Study: 22057896

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with CoQ (Med + CoQ diet)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (Med diet)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saturated fatty acid‐rich diet (SFA diet)
Number of subjects: 20
Study: 21422864

Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic-assisted vaginal hysterectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional laparoscopic-assisted vaginal hysterectomy
Number of subjects: 100
Study: 19735908

Group type: EXPERIMENTAL
Intervention: Dentifrice containing peptide; duration: 1 month
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic antigen I/II peptide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16790625

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 microg/kg bolus over 10 min, followed by continuous infusion of 0.5 microg.kg(‐1).h(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 30
Study: 15609652

Group type: EXPERIMENTAL
Intervention: Short-duration prophylaxis with 4 g of cefmetazole sodium for 2 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Long-duration prophylaxis with 14 g of cefmetazole sodium for 7 days
Number of subjects: 40
Study: 11603137

Group type: EXPERIMENTAL
Intervention: 30 mL 0.5% lignocaine and 50 mg tramadol (group B)
Number of subjects: 54

Group type: COMPARATOR
Intervention: 30 mL 0.5% lignocaine and 1 mL normal saline (group A)
Number of subjects: 54
Study: 9600792

Group type: EXPERIMENTAL
Intervention: Ibandronate treatment
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Withdrawal period after ibandronate treatment
Number of subjects: 141
Study: 8083112

Group type: EXPERIMENTAL
Intervention: Sucralfate mouth washing 1 g six times daily during irradiation (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo washing (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sucralfate mouth washing
Number of subjects: 40
Study: 2503553

Group type: EXPERIMENTAL
Intervention: Inhaled lysine-aspirin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Inhaled lysine-aspirin with terfenadine premedication
Number of subjects: 11

Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 11
Study: 955765

Group type: EXPERIMENTAL
Intervention: Home care patients after surgical procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31958285

Group type: EXPERIMENTAL
Intervention: Upper limb exercise programme (30-min daily for 12 weeks)
Number of subjects: 62
Study: 31735362

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1461
Study: 29946179

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg daily
Number of subjects: 124

Group type: COMPARATOR
Intervention: Ciprofloxacin once weekly
Number of subjects: 124
Study: 26321749

Group type: EXPERIMENTAL
Intervention: Coblation (25 patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Radiofrequency (15 patients)
Number of subjects: 40
Study: 24461029

Group type: EXPERIMENTAL
Intervention: Curcumin formulation with hydrophilic carrier, cellulosic derivatives and natural antioxidants (CHC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Curcumin phytosome formulation (CP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulation with volatile oils of turmeric rhizome (CTR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unformulated standard curcumin (CS)
Number of subjects: 0
Study: 22124354

Group type: EXPERIMENTAL
Intervention: Caffeine-containing energy drink (179 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 13
Study: 21152030

Group type: EXPERIMENTAL
Intervention: 3,4-methylenedioxyamphetamine (MDA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17414983

Group type: EXPERIMENTAL
Intervention: 1-level instrumented fusions using lamina autograft and demineralized bone matrix (Osteofil/ICM)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 2-level instrumented fusions using lamina autograft and demineralized bone matrix (Osteofil/ICM)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both 1-level and 2-level fusions
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 1-level fusions
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 2-level fusions
Number of subjects: 140
Study: 16352794

Group type: EXPERIMENTAL
Intervention: BNP levels >80 pg/mL at study entry
Number of subjects: 4497

Group type: EXPERIMENTAL
Intervention: BNP levels >80 pg/mL at 4 months
Number of subjects: 4497

Group type: EXPERIMENTAL
Intervention: BNP levels >80 pg/mL at 12 months
Number of subjects: 4497

Group type: EXPERIMENTAL
Intervention: Newly elevated BNP levels at 4 months
Number of subjects: 4497

Group type: EXPERIMENTAL
Intervention: BNP levels <80 pg/mL at study entry and <80 pg/mL at 4 months
Number of subjects: 4497
Study: 11926785

Group type: EXPERIMENTAL
Intervention: Split treatment (human regular insulin at dinner and NPH insulin at bedtime)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Mixed treatment (a mixture of human regular and NPH insulin administered before dinner)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Split treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Mixed treatment
Number of subjects: 22
Study: 10426343

Group type: EXPERIMENTAL
Intervention: Natural progesterone (vaginal cream)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 12
Study: 7768558

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (16 nmol over 3 minutes, then 16 pmol/kg per minute)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (as vehicle)
Number of subjects: 9